Markets:

Overview

News

Currencies

International

Treasuries

Avadel Pharmaceuticals plc - Ordinary Share (NQ:AVDL)

21.34 -0.01 (-0.05%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Avadel Pharmaceuticals plc - Ordinary Share

< Previous 1 2 3 4 5 6 Next >

Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge ↗

November 19, 2025

Via Stocktwits

Top 2 Health Care Stocks That May Fall Off A Cliff This Month ↗

November 17, 2025

Via Benzinga

Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal ↗

November 14, 2025

Avadel reviews Lundbeck's unsolicited $23 offer while maintaining its agreement with Alkermes as its board evaluates whether the new proposal could be superior.

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 14, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.

Via Chartmill

Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday ↗

November 14, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Earnings Outlook For Avadel Pharmaceuticals ↗

May 06, 2025

Via Benzinga

Avadel Surges 20% On Lundbeck's Surprise Alkermes-Topping Bid ↗

November 14, 2025

A new bidding war could kick off in biotech with Avadel Pharmaceuticals at the center.

Via Investor's Business Daily

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 14, 2025

Via Benzinga

Avadel Gets Acquisition Proposal From Lundbeck Weeks After Inking Agreement With Alkermes ↗

November 14, 2025

Avadel’s board of directors is of the opinion that the fresh proposal would reasonably be expected to be considered superior to the company’s existing agreement with Alkermes.

Via Stocktwits

Avadel Pharmaceuticals (NASDAQ:AVDL) Meets Minervini Trend Template with High-Growth Momentum ↗

November 06, 2025

Avadel Pharmaceuticals (AVDL) meets the Mark Minervini Trend Template with a strong technical uptrend and accelerating earnings and sales growth momentum.

Via Chartmill

Deal Dispatch: From Four Roses Bourbon To Quantum Stakes, Here Are This Week's Sector Shake Ups ↗

October 24, 2025

Four Roses, Six Flags, and Trump's potential Quantum investments: This week's deal activity involves big bets across various sectors.

Via Benzinga

Topics Government

Tesla To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Thursday ↗

October 23, 2025

Via Benzinga

This Winnebago Industries Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗

October 23, 2025

Via Benzinga

Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz ↗

October 22, 2025

Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicine. Jazz litigation settled.

Via Benzinga

Beyond The Numbers: 5 Analysts Discuss Avadel Pharmaceuticals Stock ↗

October 22, 2025

Via Benzinga

Avadel Pharmaceuticals Soars as Alkermes Announces $2.1 Billion Acquisition

October 22, 2025

DUBLIN, IRELAND – October 22, 2025 – Avadel Pharmaceuticals (NASDAQ: AVDL) shareholders are celebrating today as Alkermes plc (NASDAQ: ALKS) announced a definitive agreement to acquire the company for...

Via MarketMinute

Topics Intellectual Property

Avadel Jumps On $2.1 Billion Takeover Deal. But Buyer, Alkermes, Dives. ↗

October 22, 2025

The companies are both working in the sleep space, focusing on excessive daytime sleepiness.

Via Investor's Business Daily

Avadel Stock Rises After Acquisition Offer By Alkermes ↗

October 22, 2025

Alkermes will buy Avadel for up to $20 per share.

Via Stocktwits

What 4 Analyst Ratings Have To Say About Avadel Pharmaceuticals ↗

September 03, 2025

Via Benzinga

This Unisys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

September 03, 2025

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 21, 2025

Via Benzinga

Avadel (AVDL) Q2 Revenue Jumps 64% ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

Avadel Pharmaceuticals (NASDAQ:AVDL) Surges 6.3% in Pre-Market as Q2 Earnings Crush Estimates on Strong LUMRYZ Performance ↗

August 07, 2025

Avadel Pharmaceuticals (AVDL) beats Q2 2025 estimates with $68.1M revenue and $0.10 EPS, driven by strong LUMRYZ™ adoption. Stock surges 6.3% pre-market.

Via Chartmill

Avadel Shareholder Seeks Board Shakeup, Citing Millions Lost On Lumryz ↗

July 01, 2025

ASL demands Avadel replace its board over failures in marketing Lumryz and urging a review of strategic options

Via Benzinga

Avadel Pharmaceuticals Under Fire? Investor Reportedly Demands Board Ouster, Sale Talks, $1B In Damages ↗

June 29, 2025

ASL Strategic Value Fund plans to vote its $15 million stake against all Avadel board nominees at the July meeting and is pushing for contingent-value rights tied to potential legal payouts, according...

Via Stocktwits

Topics ETFs Intellectual Property

Earnings Scheduled For March 3, 2025 ↗

March 03, 2025

Via Benzinga

3 Stocks With Robust Growth Outlooks Insiders Are Buying

February 19, 2025

Insiders are buying these three stocks. The underlying companies have robust growth outlooks and are on track to deliver in 2025.

Via MarketBeat

There May Still Be Time to Get in on These 3 Trending Biotechs

January 20, 2025

Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.

Via MarketBeat

Topics ETFs Economy

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.